Cedilla Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., February 4, 2022 – Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that Alexandra Glucksmann, Ph.D., President and Chief Executive Officer will present a corporate update at the following upcoming investor conferences in February:

• 4^th Annual Guggenheim Oncology Conference. Company presentation on Friday, February 11, at 11:00 a.m. ET.
• BMO Biopharma Spotlight Series: Proteins – Degraders and Other Next Gen Technologies. Company presentation on Thursday, February 24, at 10:55 a.m. ET.

About Cedilla Therapeutics
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn.

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Media Contact:
Carolyn Noyes
MacDougall Advisors
cedillatx@macdougall.bio

Cedilla Therapeutics Expands Leadership Team with Key Appointments Across R&D And Finance

CAMBRIDGE, Mass.–(BUSINESS WIRE)– Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced appointments across its research and development (R&D) and finance teams, including Joshua Murtie, Ph.D., as Vice President of Biology and Chris Lindblom as Vice President of Finance. These hires are part of an ongoing initiative to expand Cedilla’s leadership and enable future growth as the company progresses its lead programs, conditional inhibitors of TEAD and CDK2, toward the clinic and continues to develop a broad portfolio of small molecule medicines that target key oncogenic drivers.

“We are delighted to expand our team with these key hires, who share our passion and commitment to developing targeted medicines that conditionally modulate proteins in their functional state,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “We look forward to Joshua and Chris’ many contributions as we continue to explore the power of our novel approach to access historically undruggable cancer drivers, advance our lead conditional inhibitor programs targeting TEAD and CDK2 into clinical development, and ultimately build Cedilla into a fully integrated organization and leader in precision medicine.”

Leadership Appointments:
Joshua Murtie, Ph.D., has been appointed Vice President of Biology. Dr. Murtie brings over ten years of industry experience to Cedilla. He worked most recently as Senior Director at Servier Pharmaceuticals, where he oversaw cancer biology, in vivo pharmacology and early-stage program management at the company’s U.S. research site. Earlier, he spent nearly seven years at Agios Pharmaceuticals in roles of increasing responsibility, ultimately serving as Senior Director and Head of Cancer Biology, with responsibility for the strategic oversight of the company’s cancer biology portfolio from early target discovery to translational research. Prior to Agios Pharmaceuticals, Dr. Murtie worked as an investigator at Sanofi and Novartis. He holds a Ph.D. in molecular and cell biology from the Uniformed Services University of the Health Sciences and completed his research fellowship at Harvard Medical School.

“I am thrilled to join Cedilla, particularly as we prepare to advance our lead programs, targeting TEAD and CDK2, into investigational new drug application-enabling studies next year,” said Dr. Murtie. “Both TEAD and CDK2 are well-known yet elusive cancer targets, which, if drugged successfully, could benefit the lives of patients living with a broad range of solid tumors. I am incredibly impressed by the collaborative and innovative culture at Cedilla and look forward to working closely with the team to translate our research efforts into precision therapies for patients in need.”
Chris Lindblom has been appointed Vice President of Finance. Over the course of his 19 years in the biotechnology industry, Mr. Lindblom has crafted long-range financial plans for public and private companies and played a key role in helping companies raise capital through private equity rounds, venture debt deals and public offerings. Prior to joining Cedilla, Mr. Lindblom served as Vice President of Finance at IFM Therapeutics, Cogen Immune Medicine (through its merger with Torque Therapeutics to form Repertoire Immune Medicines) and Warp Drive Bio (through its acquisition by Revolution Medicines). Earlier, Mr. Lindblom held various senior finance roles at Millennium Pharmaceuticals, including through the commercial launch of VELCADE®, and at Infinity Pharmaceuticals. He also served as Vice President of Finance at OvaScience and Senior Vice President of Finance and Administration at BIND Therapeutics. Mr. Lindblom holds an MBA from Boston College and a B.S. in accounting from Syracuse University. He is also a CPA.

“Since its founding, Cedilla has attracted a strong team, including leading scientists and advisors and a robust investor syndicate, to support its mission to bring a new dimension to precision oncology and deliver medicines that can offer profound benefits to patients,” said Mr. Lindblom. “I am honored to take on this role and eager to partner with my new colleagues as we continue building Cedilla for its next phase of growth.”

About Cedilla Therapeutics
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn.

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Media Contact:
Amanda Houlihan
MacDougall
cedillatx@macbiocom.com

Cedilla Therapeutics Completes $82.6M Series B Financing

Additional $25 million in funding and expansion of syndicate with leading healthcare funds, RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital

Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla Board of Directors

CAMBRIDGE, Mass., October 25, 2021 – Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today announced that it has raised an additional $25 million in an expansion of its Series B financing, bringing the total amount raised to $82.6 million. The oversubscribed Series B expansion includes new investors RA Capital Management, Janus Henderson Investors, Woodline Partners LP and Logos Capital, along with participation from existing investor Third Rock Ventures.

“We are grateful for the support from our new and existing investors, which reflects the promise of our novel approach to conditionally modulating proteins as well as the unique potential of our lead programs, inhibitors against TEAD and CDK2, two critical but historically undruggable targets,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “With this financing, we plan to accelerate and expand our development efforts by progressing our most advanced programs toward the clinic while continuing to invest in ongoing discovery efforts against additional high value cancer targets.”

Proceeds from the financing will support Cedilla’s continued growth and development of its two lead programs, an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas, and a highly selective inhibitor of CDK2/Cyclin E for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach and esophageal cancers. The company plans to initiate investigational new drug application-enabling studies for the TEAD program in the first half of 2022 and for the CDK2 program in the second half of 2022.

In conjunction with the financing, Jake Simson, Ph.D., Partner at RA Capital Management, joins Cedilla’s Board of Directors.

Dr. Glucksmann continued, “We are pleased to welcome Jake to our Board of Directors. He brings a wealth of experience advising companies from the earliest stages of company formation through their maturation into fully integrated biopharmaceutical organizations. We look forward to his many contributions as we continue to grow Cedilla into a clinical-stage organization with a robust and growing portfolio of product candidates.”

“Cedilla brings a new dimension to precision oncology by conditionally modulating proteins in their functional state,” said Jake Simson, Ph.D., Partner at RA Capital Management. “Preclinical data generated to-date suggest that Cedilla’s lead programs may challenge historical perceptions of TEAD and CDK2 as undruggable targets and could offer patients new options that would be well-tolerated and extremely effective. In addition, Cedilla’s approach, based on a deep understanding of how the cellular context modulates protein activity, could deliver superior inhibitors against a range of other key cancer drivers. I look forward to partnering with the team with the aim to deliver a broad portfolio of small molecule medicines, each with potential profound benefit to patients.”

About Cedilla Therapeutics
Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn.

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Media Contact:
Amanda Houlihan
MacDougall
cedillatx@macbiocom.com

Cedilla Therapeutics Unveils Lead Programs for the Conditional Inhibition of TEAD and CDK2, Two High Value and Historically Undruggable Cancer Drivers

–Conditional modulation of proteins in their functional state opens a new dimension in precision oncology–

–IND-enabling studies expected to initiate in 1H 2022 for TEAD program and in 2H 2022 for CDK2 program–

CAMBRIDGE, Mass., October 21, 2021 – Cedilla Therapeutics, a biotechnology company bringing a new dimension to precision oncology, today revealed its two lead conditional inhibitor programs: an inhibitor of TEAD for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas; and a highly selective inhibitor of CDK2 for the treatment of multiple tumor types, including CDK4/6-resistant breast cancer, ovarian, uterine, stomach, and esophageal cancers. Both programs are wholly owned by Cedilla. In addition, Cedilla is pursuing discovery research efforts against a portfolio of high value cancer targets.

“Over the past three years, we have built an integrated suite of capabilities that enable us to understand the relevant functional states of important yet elusive cancer targets, and identify previously unrecognized small molecule binding sites,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Today, we are excited to announce our two lead programs from our internal efforts to discover conditional inhibitors: an inhibitor of TEAD and a highly selective inhibitor of CDK2. We look forward to advancing these programs closer to the clinic and creating novel medicines with the potential to deliver profound benefit to patients.”

The discovery of both programs was enabled by Cedilla’s novel approach to developing small molecule conditional inhibitors. Cedilla recognizes proteins as dynamic entities, whose function is orchestrated by inter-molecular associations and post-translational tailoring. By accounting for the native full-length protein with relevant post-translational modifications, protein-protein interactions and sub-cellular localization, Cedilla is able to understand proteins in their functional state to discover new ways to access key cancer drivers that have been considered undruggable.

“Since our founding, we have worked to develop a deep understanding of high-value, historically inaccessible targets, and to identify new vulnerabilities that may enable us to drug them more effectively, delivering superior clinical benefit,” said Brian Jones, Ph.D., Chief Scientific Officer. “Based on preclinical data, I believe our TEAD and CDK2 programs have clear advantages relative to historical approaches, offering the opportunity for preferential clinical utility, in terms of targeted efficacy or combinability with other therapeutic mechanisms. We look forward to advancing both programs into IND-enabling studies next year.”

About Cedilla’s TEAD Program

TEAD (transcriptional enhanced associate domain) is a key component of the Hippo signaling pathway that is aberrantly regulated in solid tumors such as mesothelioma and certain squamous cell carcinomas. TEAD is also increasingly implicated in resistance to targeted therapies, including those for the treatment of EGFR-mutated and KRAS-mutated lung cancer.

Cedilla’s program is designed to inhibit the function of TEAD by preventing a post-translational modification required for full function. The company’s portfolio of TEAD inhibitors encompasses multiple chemotypes with different effects on TEAD isoforms and cofactors, providing Cedilla a range of starting points for selecting a candidate with an optimal profile for effective and combinable TEAD inhibition. Cedilla plans to be conducting investigational new drug (IND) application-enabling studies in the first half of 2022.

About Cedilla’s CDK2 Program

CDK2 (cyclin dependent kinase 2) has been a major target of interest for cancer indications driven by amplification or high levels of Cyclin E, including in roughly half of patients with CDK4/6-resistant breast cancer. In addition, Cyclin E amplification drives genetically defined subsets of ovarian, uterine, stomach and esophageal cancers. The CDK2-Cyclin E cancer node has remained inaccessible due to challenges achieving selectivity over other CDKs (cyclin dependent kinases), particularly CDK1, and Cyclin E isoforms.

Cedilla has developed a unique series of inhibitors that bind to a previously unreported site on the CDK2-Cyclin E complex with unprecedented selectivity, potentially offering a substantial advance over two decades of industry efforts. Preclinical characterization suggests that the exquisite selectivity of Cedilla’s inhibitor could result in a better safety profile compared to traditional kinase inhibitors, particularly with respect to dose-limiting hematological toxicities. Cedilla plans to be conducting IND application-enabling studies in the second half of 2022. In addition, based on its unique insights into Cyclin biology, Cedilla has the potential to pursue additional drug discovery programs against related targets.

About Cedilla Therapeutics

Cedilla Therapeutics is bringing a new dimension to precision oncology. We have discovered new ways to selectively inhibit oncogenic drivers with small molecules that conditionally modulate proteins in their functional state. Our conditional inhibitors are unlocking critical and elusive cancer targets including TEAD and CDK2. We are a driven and patient-focused team. Follow our journey at www.cedillatx.com and LinkedIn.

Investor Contact:
Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Media Contact:
Amanda Houlihan
MacDougall
cedillatx@macbiocom.com

Cedilla Therapeutics Appoints Chris Bowden, M.D. to its Board of Directors

CAMBRIDGE, Mass., April 21, 2021 – Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Chris Bowden, M.D., to its Board of Directors.

“Chris brings tremendous industry experience to Cedilla, with more than two decades of oncology drug development leadership, having successfully brought multiple novel medicines to market,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “His insights will be particularly valuable as we prepare to nominate our first two precision therapeutic oncology drug candidates. We look forward to his many contributions as we advance our lead programs and work to build a broad portfolio of small molecule medicines that can redirect the course of disease and deliver profound benefit to patients.”

Dr. Bowden joined Agios as Chief Medical Officer in May 2014, leading clinical development activities that resulted in the TIBSOVO® approvals for IDH1 mutation positive acute myeloid leukemia in the U.S. Prior to joining Agios, Dr. Bowden was vice president product development oncology, franchise lead (Signaling Group) at Genentech, Inc., a member of the Roche Group. During Dr. Bowden’s eight years at Genentech, he was responsible for the successful development of a number of novel targeted oncology medicines, including Zelboraf™ for patients with BRAF V600E positive melanoma and Tarceva™ for patients with EGFr activating mutation positive, non-small cell lung cancer. From 2003 to 2006, Dr. Bowden was the executive director for EMEA (Europe, Middle East, Africa) regions for Bristol-Myers Squibb. In this role, he led medical affairs strategies for cancer, immunology and pain medicines. Earlier, Dr. Bowden held positions of increasing responsibility in oncology clinical development at Pharmacia Corporation and Janssen Pharmaceutical, Inc. Prior to his industry experience, Dr. Bowden was on the oncology faculty at the University of Virginia Health Science Center where he participated in numerous industry and cooperative group trials. Dr. Bowden received his medical degree from Hahnemann University School of Medicine in Philadelphia followed by internal medicine training at Roger Williams Medical Center and the Providence VA Medical Center, Rhode Island. He completed his medical oncology fellowship at the National Cancer Institute Medicine Branch. Dr. Bowden is board certified in internal medicine and medical oncology, and he serves on the board of directors at Ziopharm Oncology Inc.

“This is an exciting time to join Cedilla’s Board of Directors,” said Dr. Bowden. “Cedilla’s unique approach to addressing undruggable targets, coupled with the team’s deep drug development expertise, has the potential to bring much needed therapies to patients. I look forward to working with the board and the management team to advance the next generation of targeted molecular therapeutics, with the goal of enabling even greater reach, precision and impact.”

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com

Cedilla Therapeutics Announces Appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance

CAMBRIDGE, Mass., April 5, 2021 – Cedilla Therapeutics, a venture-backed preclinical biotechnology company developing novel small molecules for cancer and other diseases, today announced the appointment of Véronique Riethuisen as Chief Business Officer and Head of Finance. In this newly created role, Ms. Riethuisen will oversee corporate development, finance and strategic planning and serve as treasurer and company secretary.

“We are thrilled to welcome Véronique to Cedilla. She has an impressive track record shaping and building early and late-stage portfolios for leading biopharmaceutical companies,” said Alexandra Glucksmann, Ph.D., President and Chief Executive Officer of Cedilla Therapeutics. “Véronique’s substantial leadership experience, coupled with her background in corporate and business development, will be instrumental in growing Cedilla. We look forward to her contributions as we execute on our vision of leveraging our novel small molecule drug discovery approach to address the needs of patients with cancer and other diseases.”

“I am honored to join the Cedilla team. Cedilla has developed a novel approach to addressing undruggable targets for the treatment of cancers and diseases caused by protein dysregulation,” said Ms. Riethuisen. “I look forward to working together with my new colleagues to progress a growing portfolio of promising medicines for the benefit of patients.”

Ms. Riethuisen brings over 25 years of experience in global business development, M&A and alliance management leadership to Cedilla. Most recently, Ms. Riethuisen served as Senior Vice President, Global Business Development and Strategic Alliance Management at Ipsen where she helped build Ipsen’s rare disease franchise by acquiring and licensing multiple innovative assets for the treatment of fibrodysplasia ossificans progressiva. She also negotiated Ipsen’s global agreement with Debiopharm for Decapeptyl®, an achievement recognized with the 2020 Award for “Long-Established Alliance” from the Association of Strategic Alliance Professionals. Prior to Ipsen, Ms. Riethuisen was Vice President, Head of Global Transactions at Takeda where she led a team that, in just one year, successfully landed over 20 deals transforming the company’s gastrointestinal and regenerative medicine portfolios. Earlier, Ms. Riethuisen held various business development, M&A and alliance management roles of increasing responsibility at Pfizer, Teva, Bristol Myers Squibb and Monsanto.  Ms. Riethuisen currently serves as an Executive Coach for the MassNextGen program mentoring first-time female chief executive officers, and she teaches a Business Development Fundamentals course annually in conjunction with the BIO Annual Conference. Ms. Riethuisen holds a bachelor and master’s degree in Applied Economics from the University of Brussels (ULB), Belgium.

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted novel small molecule therapeutics directed to unrecognized allosteric binding sites and uncovering novel ways to access key disease drivers. The company employs a target-centric approach and integrates a multidisciplinary set of tools to design novel drug discovery screens that recapitulate the relevant functional state of validated disease drivers that have, to date, eluded conventional therapeutic modalities. For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-120

Cedilla and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

CHENGDU, China– Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Cedilla Therapeutics, Inc. (“Cedilla”), a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation. The companies will conduct joint research to identify and develop drug candidates directed to a validated, high-value target in oncology that has remained beyond the reach of previous efforts.

HitGen is a world leading biotech company in DNA encoded library-screening, a high throughput compound screening technology, where more than 100,000 times larger libraries can be used than in traditional drug discovery. The platform thus enables faster identification of innovative drug candidates with improved target specificity and enhanced drug-like characteristics.

Pursuant to the terms of the collaboration agreement, HitGen has successfully applied its DEL technology and discovered program compounds that met certain criteria, and Cedilla has received an exclusive license to these compounds as well as associated IP for further development and commercialization.  HitGen will be eligible for milestone payments and sublicensing income from Cedilla as the project progresses, in addition to research payments and upfront license fee.

“HitGen is a perfect partner for us in this program, with their cutting-edge DEL platform for screening. Their technology is well established and is now widely used by leading global pharmaceutical and biotech companies,” said Dr. Alexandra Glucksmann, President and CEO of Cedilla. “With HitGen’s support, we are able to accelerate our ongoing efforts to pursue a breadth of high-value oncology targets that have eluded conventional therapeutic modalities. We are very pleased with the program compounds discovered by HitGen to date, are excited to advance these programs forward as we pursue our mission of delivering profound benefit to patients in areas of high unmet need.”

“We are delighted to enter this collaboration with Cedilla, and believe their unique approach to identifying functionally-relevant proteoforms represents a powerful advance in how we think about treating diseases caused by protein dysregulation,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen. “We believe the collaboration will reinforce the role and reputation of HitGen’s platform in the rapidly developing field of DEL and further demonstrates the power of our DEL platform to discover novel small molecules against a variety of targets. We are working closely with Cedilla scientists and have seen early success towards generating new small-molecule lead compounds for their research programs to help bring transformative medicines to patients.”

About Cedilla Therapeutics, Inc.

Cedilla is a private biotechnology company developing targeted small molecule medicines for the treatment of cancer and other diseases caused by protein dysregulation. The company employs a target-centric approach, focusing on scientifically-validated drivers of disease that have eluded conventional therapeutic modalities. Cedilla identifies functionally-relevant proteoforms, or protein states, creating novel opportunities for therapeutic intervention. For more information, visit www.cedillatx.com.

About HitGen Inc.

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug discovery research centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs). HitGen’s DELs contain over 400 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.

For more information, please call:
+86-28-85197385
or visit:
www.hitgen.com

For business development: 
bd@hitgen.com

For investor inquiries: 
investors@hitgen.com

For media inquiries: 
media@hitgen.com

Investor Contact (Cedilla):

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-1200

Cedilla Therapeutics Announces $57.6 Million Series B Financing

Financing Co-Led by Leading Public Healthcare Funds, Casdin Capital and Boxer Capital of Tavistock Group

CAMBRIDGE, Mass., October 13, 2020 – Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $57.6 million Series B financing. The financing was co-led by Casdin Capital and Boxer Capital of Tavistock Group and included new investors Eli Lilly and Company and Schroder Adveq, as well as other undisclosed institutional investors, along with existing investor Third Rock Ventures. In connection with the financing, Eli Casdin, Chief Investment Officer and Founder of Casdin Capital, and Dominik Naczynski, Senior Vice President at Boxer Capital, will join the Company’s Board of Directors.

“Cedilla was founded on the understanding that therapeutic targets exist in multiple proteoforms, or protein states, which can be evaluated for functional relevance and exploited to create novel opportunities for intervention, even where conventional approaches have failed,” said Alexandra Glucksmann, Ph.D., Cedilla’s president and chief executive officer. “Over the past two years, we have honed our integrated approach and we are now prepared to advance target-specific efforts toward the clinic. We appreciate the support of our new and existing investors, which will enable us to name our first two development candidates, expand our discovery-stage research and work toward our goal of delivering novel small molecules that can redirect the course of disease and deliver profound benefit to patients.”

Cedilla identifies previously unexploited proteoforms of high-value targets. While prior attempts to drug these targets have focused only on their canonical states, Cedilla has discovered the means to affect function or stability by engaging pivotal, post-translationally modified states. Cedilla’s product candidates are designed with mechanisms best fit to modulate these functionally-relevant proteoforms, which may include protein inhibition or degradation. Proceeds from this financing will support ongoing efforts to build a broad portfolio of small molecule medicines, including the identification and preclinical development of Cedilla’s first two product candidates.

“Cedilla is establishing an entirely new approach to drug development, based on a deep understanding of proteomics and a unique ability to identify and modulate functionally-relevant proteoforms of high-value targets,” said Eli Casdin, Chief Investment Officer and Founder of Casdin Capital. “It is a big idea with powerful potential and we are excited to partner with the management team to accelerate the next stage of the company’s growth.”

About Cedilla Therapeutics

Cedilla Therapeutics is a private biotechnology company developing targeted small molecule medicines for the treatment of cancer and other diseases caused by protein dysregulation. The company employs a target-centric approach, focusing on scientifically-validated drivers of disease that have eluded conventional therapeutic modalities.  Cedilla identifies functionally-relevant proteoforms, or protein states, creating novel opportunities for therapeutic intervention.

For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Investor Contact:

Hannah Deresiewicz
Stern Investor Relations, Inc.
hannah.deresiewicz@sternir.com
212-362-1200

Cedilla Therapeutics Appoints Justin Birtz as Vice President, People and Culture

CAMBRIDGE, Mass. Oct. 23, 2019 — Cedilla Therapeutics, a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies,today announced the appointment of Justin Birtz as vice president, people and culture. Mr. Birtz brings to the role nearly two decades of talent and organizational development experience.

Mr. Birtz joins Cedilla from BitSight, where he was director, people operations. There, Mr. Birtz designed and developed the company’s first programs in leadership development, new leader onboarding and performance management with the goal of evolving company culture and inspiring new ways of thinking. In his role at Cedilla, Mr. Birtz will align Cedilla’s mission, values and talent strategy to connect, engage and develop remarkable professionals who share a passion for improving the lives of patients.

“Justin will be instrumental in building internal initiatives to assure that each individual within our deeply skilled network can impact the company and its success,” said Sandra Glucksmann, Ph.D., chief executive officer of Cedilla. “I’m delighted to welcome him to the team.”

Prior to BitSight, Mr. Birtz was director, HR business partnership and director, learning and organizational development at iRobot. Previously, Mr. Birtz spearheaded growth initiatives as an HR manager at Imprivata, Teladoc and Symbotic. He holds a master’s degree in human resource management from Framingham State University and a bachelor’s degree in management from Isenberg School of Management, University of Massachusetts at Amherst.

“Cedilla is composed of many talented scientists and leaders,” commented Mr. Birtz. “I am excited to lead the efforts to develop this team, capitalizing on a diverse workforce that shares a passion for helping patients.”

Added Dr. Glucksmann: “Our company recognizes the importance of meeting goals together. We celebrate the achievements that move us one step closer to building an industry-leading platform and deep pipeline of targets to treat diseases caused by protein dysfunction.”

About Cedilla Therapeutics

Cedilla Therapeutics is a biotechnology company dedicated to improving the lives of patients by delivering the next generation of targeted cancer therapies that precisely modulate critical disease-driving proteins. The company employs an integrated approach that uses small molecules to assess multiple mechanisms for restoring protein homeostasis. Cedilla harnesses the mechanisms most likely to succeed for individual, high-value oncology targets. While adding to industry knowledge of protein degradation, Cedilla is building a powerful, industry-leading platform and broad pipeline of therapeutics. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.

For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Media Contact:

Molly Rusert
Ten Bridge Communications
molly@tenbridgecommunications.com
612-232-2084

Cedilla Therapeutics Appoints Delphine Collin, Ph.D., as Vice President, Biomolecular Sciences

CAMBRIDGE, Mass. May 14, 2019—Cedilla Therapeutics today announced the appointment of Delphine Collin, Ph.D., as vice president, biomolecular sciences. In this role, she will advance Cedilla’s work to develop and leverage the biophysical and biochemical understanding of ligand-induced stabilization and degradation of therapeutically relevant protein targets.

“Delphine is an accomplished leader with a proven track record of developing successful discovery strategies and advancing preclinical projects,” said Brian Jones, Ph.D., Cedilla’s chief scientific officer. “Her deep expertise in protein characterization and protein-small molecule interactions will be invaluable as we explore promising new tools to modulate protein stability.”

Collin most recently served as chief innovation officer of HarkerBIO, a contract research organization focused on the structural enablement of early discovery research. Previously, she served as senior principal scientist at Boehringer Ingelheim (BI) and led a biophysics group focused on lead identification and optimization in the small molecule drug discovery group. While at BI, Collin also started her own consulting firm, Delphine Collin Consulting, LLC., where she supported companies with specialized biophysical approaches to drug discovery. Prior to BI, Collin was a research fellow at Merck & Co. Collin holds a Ph.D. in biophysical chemistry and doctorate in pharmaceutical sciences from the University of Paris XI, France.

“Cedilla is pursuing several exciting new avenues for protein degradation, and I’m delighted to join the team,” Collin said. “We’re committed to broadening the reach of small molecule therapeutics to address cancer and other diseases caused by protein dysregulation.”

About Cedilla Therapeutics

Cedilla Therapeutics is discovering and exploiting unique insights into protein stability. Cedilla’s integrated, multi-faceted approach has the potential to broaden the reach of small molecules by generating therapeutics that degrade protein targets as their primary mechanism of action. The approach harnesses intrinsic degradation pathways that are upstream of ubiquitination. Cedilla is focused on destabilizing oncoprotein targets using a product engine that is also applicable to targets outside of oncology. Cedilla was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.

For more information, please visit www.cedillatx.com or follow us on LinkedIn.

Media Contact:

Stephanie Simon
Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333